The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2022

Filed:

Feb. 27, 2020
Applicant:

Nitto Denko Corporation, Osaka, JP;

Inventors:

Kenjirou Minomi, Osaka, JP;

Jihua Liu, San Marco, CA (US);

Li Wang, San Diego, CA (US);

Bharat Majeti, San Diego, CA (US);

Roger Adami, Carlsbad, CA (US);

Wenbin Ying, San Diego, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2005.12); A61K 48/00 (2005.12); C12N 15/113 (2009.12); A61B 5/00 (2005.12); A61K 49/00 (2005.12); C07D 311/30 (2005.12); C07F 9/6533 (2005.12); C12Q 1/02 (2005.12); G01N 33/58 (2005.12); A61K 31/713 (2005.12);
U.S. Cl.
CPC ...
A61B 5/0071 (2012.12); A61K 49/0021 (2012.12); C07D 311/30 (2012.12); C07F 9/6533 (2012.12); C12N 15/113 (2012.12); C12N 15/1135 (2012.12); C12N 15/1137 (2012.12); C12Q 1/02 (2012.12); G01N 33/582 (2012.12); H05K 999/99 (2012.12); A61K 31/713 (2012.12); C12N 2310/14 (2012.12); C12N 2310/322 (2012.12); C12N 2310/344 (2012.12); C12N 2310/3515 (2012.12); C12N 2310/531 (2012.12); C12N 2320/30 (2012.12); C12N 2320/32 (2012.12); C12N 2320/35 (2012.12); C12N 2320/53 (2012.12);
Abstract

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.


Find Patent Forward Citations

Loading…